| Tzield |
761183 |
001 |
351(a) |
teplizumab-mzwv |
Injection |
Intravenous |
2MG/2ML (1MG/ML) |
Single-Dose Vial |
2022/11/17
|
Provention Bio, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Elahere |
761310 |
001 |
351(a) |
mirvetuximab soravtansine-gynx |
Injection |
Intravenous |
100MG/20ML (5MG/ML) |
Single-Dose Vial |
2022/11/14
|
ImmunoGen, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Erelzi |
761042 |
004 |
351(k) Biosimilar |
etanercept-szzs |
For Injection |
Subcutaneous |
25MG |
Multi-Dose Vial |
2022/11/10
|
Sandoz Inc. |
Disc |
Licensed |
etanercept |
Enbrel |
| Rotarix |
125265 |
002 |
351(a) |
Rotavirus Vaccine, Live, Oral |
Suspension |
Oral |
106.0CCID50 |
Tube |
2022/11/04
|
GlaxoSmithKline Biologicals |
Disc |
Licensed |
|
|
| Rotarix |
125265 |
003 |
351(a) |
Rotavirus Vaccine, Live, Oral |
Suspension |
Oral |
106.0CCID50 |
Oral Applicator |
2022/11/04
|
GlaxoSmithKline Biologicals |
Rx |
Licensed |
|
|
| Tecvayli |
761291 |
001 |
351(a) |
teclistamab-cqyv |
Injection |
Subcutaneous |
30MG/3ML (10MG/ML) |
Single-Dose Vial |
2022/10/25
|
Janssen Biotech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Tecvayli |
761291 |
002 |
351(a) |
teclistamab-cqyv |
Injection |
Subcutaneous |
153MG/1.7ML (90MG/ML) |
Single-Dose Vial |
2022/10/25
|
Janssen Biotech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Imjudo |
761289 |
001 |
351(a) |
tremelimumab-actl |
Injection |
Intravenous |
25MG/1.25ML (20MG/ML) |
Single-Dose Vial |
2022/10/21
|
AstraZeneca AB |
Rx |
Licensed |
N/A |
N/A |
| Imjudo |
761289 |
002 |
351(a) |
tremelimumab-actl |
Injection |
Intravenous |
300MG/15ML (20MG/ML) |
Single-Dose Vial |
2022/10/21
|
AstraZeneca AB |
Rx |
Licensed |
N/A |
N/A |
| Menveo |
125300 |
002 |
351(a) |
Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine |
Injection |
Intramuscular |
0.5ML |
Single-Dose Vial |
2022/10/14
|
GlaxoSmithKline Biologicals |
Rx |
Licensed |
|
N/A |
| Vegzelma |
761268 |
001 |
351(k) Biosimilar |
bevacizumab-adcd |
Injection |
Intravenous |
100MG/4ML (25MG/ML) |
Single-Dose Vial |
2022/09/27
|
CELLTRION, Inc. |
Rx |
Licensed |
bevacizumab |
Avastin |
| Vegzelma |
761268 |
002 |
351(k) Biosimilar |
bevacizumab-adcd |
Injection |
Intravenous |
400MG/16ML (25MG/ML) |
Single-Dose Vial |
2022/09/27
|
CELLTRION, Inc. |
Rx |
Licensed |
bevacizumab |
Avastin |
| Skyrizi |
761105 |
004 |
351(a) |
risankizumab-rzaa |
Injection |
Subcutaneous |
180MG/1.2ML (150MG/ML) |
Single-Dose Cartridge |
2022/09/23
|
AbbVie Inc. |
Rx |
Licensed |
N/A |
N/A |
| Skysona |
125755 |
001 |
351(a) |
elivaldogene autotemcel |
Injection |
Intravenous |
2-30 × 10^6 CELL/ML |
Bag |
2022/09/16
|
Bluebird Bio Inc. |
Rx |
Licensed |
|
|
| Rolvedon |
761148 |
001 |
351(a) |
eflapegrastim-xnst |
Injection |
Subcutaneous |
13.2MG/0.6ML |
Pre-Filled Syringe |
2022/09/09
|
Spectrum Pharmaceuticals, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Daxxify |
761127 |
001 |
351(a) |
daxibotulinumtoxinA-lanm |
For Injection |
Intramuscular |
50UNITS |
Single-Dose Vial |
2022/09/07
|
Revance Therapeutics, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Daxxify |
761127 |
002 |
351(a) |
daxibotulinumtoxinA-lanm |
For Injection |
Intramuscular |
100UNITS |
Single-Dose Vial |
2022/09/07
|
Revance Therapeutics, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Stimufend |
761173 |
001 |
351(k) Biosimilar |
pegfilgrastim-fpgk |
Injection |
Subcutaneous |
6MG/0.6ML |
Pre-Filled Syringe |
2022/09/01
|
Fresenius Kabi USA, LLC |
Rx |
Licensed |
pegfilgrastim |
Neulasta |
| Spevigo |
761244 |
001 |
351(a) |
spesolimab-sbzo |
Injection |
Intravenous |
450MG/7.5ML (60MG/ML) |
Single-Dose Vial |
2022/09/01
|
Boehringer Ingelheim Pharmaceuticals, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Xenpozyme |
761261 |
001 |
351(a) |
olipudase alfa-rpcp |
For Injection |
Intravenous |
20MG |
Single-Dose Vial |
2022/08/31
|
Genzyme Corporation |
Rx |
Licensed |
N/A |
N/A |